Search is Powered by Google
Cancer / Oncology News

Friendly Gut Bacteria Boost Immune Response To Tumors

Main Category: Cancer / Oncology
Also Included In: GastroIntestinal / Gastroenterology;  Biology / Biochemistry
Article Date: 30 Jul 2007 - 2:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article


Current Article Ratings:

Patient / Public:4 and a half stars

4.5 (2 votes)

Health Professional:4 and a half stars

4.5 (2 votes)

Article Opinions: 0 posts

One potent, immune-based treatment for cancer is total body irradiation (TBI). This approach first depletes the body of the population of immune cells known as lymphocytes and then involves the adoptive transfer of tumor-specific T cells to the patient. Lymphodepletion has previously been shown to improve the ability of tumor-specific T cells to cause tumor regression. In a study appearing online on in advance of publication in the August print issue of the Journal of Clinical Investigation, Nicholas Restifo and colleagues from the National Cancer Institute show that, in mice, lymphodepletion does not fully account for the tumor regression observed following TBI. They show that a disruption of the population of bacteria that normally reside in the gut without causing disease also plays a role in the effectiveness of this therapeutic approach for cancer.

A specific population of bacteria present in our gut is crucial to our health. However, some treatments for cancer, particularly those that deplete the body's immune cells, have high potential to disrupt the natural balance between our bodies and these commensal microorganisms, causing disease. Restifo and colleagues subjected mice genetically deficient in lymphocytes to TBI and found that, like TBI-treated mice with intact lymphocytes, TBI was still able to positively augment the function of adoptively transferred tumor-specific CD8+ T cells and cause tumor regression. This surprising result indicated that another mechanism for the efficacy of TBI also exists. They found that in these mutant, irradiated mice the lining of their gut was injured, allowing the passage of commensal bacteria from the gut to the lymph nodes, where the immune response to their presence increased the activation of tumor-specific CD8+ T cells and resulted in tumor regression. This effect was found to involve toll-like receptor 4. Conversely, a reduction in the number of host microorganisms by the use of antibiotics reduced the beneficial effects of TBI on tumor regression in these animals. In summary, the results of the study demonstrate that the disruption of the host/microorganism balance by TBI and the resulting transient bacterial infection is a key mechanism driving the increased reactivity of tumor-specific CD8+ T cells and subsequent tumor regression in mice.

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

TITLE: Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling

AUTHOR CONTACT:
Nicholas P. Restifo or Chrystal M. Paulos
National Cancer Institute, Bethesda, Maryland, USA.

Source: Brooke Grindlinger
Journal of Clinical Investigation




Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Understanding And Treating Triple-Negative Breast Cancer
07 Jan 2009
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...